ATE429219T1 - Therapeutisches mittel ((-)-bpap) gegen drogenabhängigkeit - Google Patents

Therapeutisches mittel ((-)-bpap) gegen drogenabhängigkeit

Info

Publication number
ATE429219T1
ATE429219T1 AT05809728T AT05809728T ATE429219T1 AT E429219 T1 ATE429219 T1 AT E429219T1 AT 05809728 T AT05809728 T AT 05809728T AT 05809728 T AT05809728 T AT 05809728T AT E429219 T1 ATE429219 T1 AT E429219T1
Authority
AT
Austria
Prior art keywords
therapeutic agent
substance
bpap
drug addiction
craving
Prior art date
Application number
AT05809728T
Other languages
English (en)
Inventor
Tsuneyuki Yamamoto
Fumio Yoneda
Kazuhiko Morimoto
Original Assignee
Univ Kyushu Nat Univ Corp
Fujimoto Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyushu Nat Univ Corp, Fujimoto Co Ltd filed Critical Univ Kyushu Nat Univ Corp
Application granted granted Critical
Publication of ATE429219T1 publication Critical patent/ATE429219T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05809728T 2004-11-25 2005-11-21 Therapeutisches mittel ((-)-bpap) gegen drogenabhängigkeit ATE429219T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004339996A JP5030194B2 (ja) 2004-11-25 2004-11-25 薬物依存症治療剤
PCT/JP2005/021344 WO2006057211A1 (ja) 2004-11-25 2005-11-21 薬物依存症治療剤

Publications (1)

Publication Number Publication Date
ATE429219T1 true ATE429219T1 (de) 2009-05-15

Family

ID=36497948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05809728T ATE429219T1 (de) 2004-11-25 2005-11-21 Therapeutisches mittel ((-)-bpap) gegen drogenabhängigkeit

Country Status (14)

Country Link
US (2) US7825158B2 (de)
EP (1) EP1815853B1 (de)
JP (1) JP5030194B2 (de)
KR (1) KR101096416B1 (de)
CN (1) CN101065123B (de)
AT (1) ATE429219T1 (de)
AU (1) AU2005308258B2 (de)
CA (1) CA2589289C (de)
DE (1) DE602005014135D1 (de)
DK (1) DK1815853T3 (de)
ES (1) ES2325790T3 (de)
IL (1) IL183028A (de)
SI (1) SI1815853T1 (de)
WO (1) WO2006057211A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2690945C (en) 2007-06-21 2015-07-21 Fujimoto Co., Ltd. Transdermal or transmucosal pharmaceutical composition comprising 1-(benzofuran-2-yl)-2-propylaminopentane
AU2014371437B2 (en) 2013-12-25 2020-01-30 Fujimoto Co., Ltd. Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder
EP3226852B1 (de) 2014-12-05 2020-03-18 Semmelweis University Arylalkylamin-verbindungen zur verwendung bei der vorbeugung oder behandlung von krebs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948803A (en) 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
JPH03500411A (ja) 1987-10-07 1991-01-31 マトリックス　テクノロジーズ　インコーポレーテッド コカイン中毒の処置および治療薬
DE3930282A1 (de) 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
JPH1129476A (ja) 1997-05-16 1999-02-02 Grelan Pharmaceut Co Ltd 麻薬依存抑制剤
JP4499208B2 (ja) * 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション 新規な光学活性アミノペンタン誘導体
JP4691230B2 (ja) * 2000-04-11 2011-06-01 株式会社フジモト・コーポレーション 光学活性１−（ベンゾフラン−２−イル）−２−プロピルアミノペンタンの製造方法
JP4953040B2 (ja) * 2001-09-19 2012-06-13 株式会社フジモト・コーポレーション アポトーシス抑制剤
JP4953041B2 (ja) * 2001-09-19 2012-06-13 株式会社フジモト・コーポレーション アポトーシス抑制剤

Also Published As

Publication number Publication date
JP5030194B2 (ja) 2012-09-19
CN101065123B (zh) 2012-02-15
ES2325790T3 (es) 2009-09-17
EP1815853A1 (de) 2007-08-08
EP1815853B1 (de) 2009-04-22
IL183028A0 (en) 2007-10-31
EP1815853A4 (de) 2008-03-19
DK1815853T3 (da) 2009-08-03
IL183028A (en) 2011-12-29
WO2006057211A1 (ja) 2006-06-01
KR20070091610A (ko) 2007-09-11
US7825158B2 (en) 2010-11-02
DE602005014135D1 (de) 2009-06-04
US20080004337A1 (en) 2008-01-03
CA2589289C (en) 2013-04-30
US20100298426A1 (en) 2010-11-25
CN101065123A (zh) 2007-10-31
JP2006151820A (ja) 2006-06-15
US8318799B2 (en) 2012-11-27
AU2005308258B2 (en) 2011-02-24
CA2589289A1 (en) 2006-06-01
AU2005308258A1 (en) 2006-06-01
SI1815853T1 (sl) 2009-10-31
KR101096416B1 (ko) 2011-12-21
HK1113309A1 (en) 2008-10-03

Similar Documents

Publication Publication Date Title
CY2014042I2 (el) Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζολιου, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους
WO2004066912A3 (en) Anti-inflammatory compositions and uses thereof
TW200621937A (en) New compound and organic light emitting device using the same
EP1943004A4 (de) Rutheniumkatalysierte cycloaddition von alkinen und organischen aziden
NO20072965L (no) Potentiatorer av glutamatreceptorer
DK1776011T3 (da) Fungicid sammensætning, indeholdende et syreamidderivat
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
EP1930329A4 (de) 1,3,5-triazinderivat, verfahren zur herstellung davon und dieses als komponente enthaltende organische elektrolumineszenzvorrichtung
TW200700319A (en) Method for purifying hydrogen chloride
DE602007011897D1 (de) Neue aminoalkohol-substituierte aryldihydroisochinolinone, herstellungsverfahren und ihre verwendung als medikamente
CO5601045A2 (es) Procedimiento para la fabricacion de compuestos organicos
DE502005011078D1 (de) Herstellung von 3-pentennitril aus 1,3-butadien
AR064955A1 (es) Composicion y metodo para estabilizar ingredientes sensibles
NO20050019L (no) Polytylenglykolaldehyd-derivater
IL183028A0 (en) Therapeutic agent for drug dependence
BRPI0519157B8 (pt) composição, e, uso da mesma
NL1030010A1 (nl) 4-Amino-gesubstitueerde-2-gesubstitueerde-1,2,3,4- tetrahydrochinolineverbindingen.
TW200621843A (en) Solvent composition
DE602006008937D1 (de) N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten
DE602004019698D1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
EA200601090A1 (ru) Получение 2,3-цис-замещённых 2-арилпропеналей
CY1108865T1 (el) Υποκατεστημενες 2,5-διαμινομευθυλο-1η-πυρρολες
RU2007134356A (ru) Способ снижения уровня тревожности в эксперименте
EA200900479A1 (ru) СПОСОБ ПОЛУЧЕНИЯ γ-БУТИРОЛАКТОНОВ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1815853

Country of ref document: EP